Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00781456 · ClinicalTrials.gov registry record · Phase 2
A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches
A Phase 2 study, sponsored by Duramed Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT00781456 is a Phase 2 study that has completed, run by Duramed Research. The registered enrollment target is 109 participants.
The verdict
NCT00781456, a Phase 2 study, has completed, sponsored by Duramed Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the efficacy of a 91-day extended cycle oral contraceptive compared to placebo for decreasing the frequency and severity of menstrually-related migraine headaches.
Interventions
- DRUG Placebo
- DRUG 91-day Levonorgestrel Oral Contraceptive
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00781456
The ClinicalTrials.gov registry entry for NCT00781456 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duramed Research, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00781456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00781456 about?
NCT00781456 is a clinical study titled "A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches". This study is being conducted to evaluate the efficacy of a 91-day extended cycle oral contraceptive compared to placebo for decreasing the frequency and severity of menstrually-related migraine headaches.
What is the current status of trial NCT00781456?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2009-01. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00781456?
The interventions under investigation include: Placebo (DRUG), 91-day Levonorgestrel Oral Contraceptive (DRUG).
Who is sponsoring clinical trial NCT00781456?
This trial is sponsored by Duramed Research, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.